02:14 PM EDT, 08/12/2024 (MT Newswires) -- Compass Therapeutics ( CMPX ) shares were up 7% in recent trading on Monday, after the company posted revenue above consensus.

The company reported Q2 net loss of $0.10 per diluted share, widening from a loss of $0.09 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.10.

Revenue for the quarter ended June 30 was $850,000, compared with no revenue a year earlier.

Analysts surveyed by Capital IQ expected no revenue.

Cash and cash equivalents totaled $146 million compared with $152 million as of Dec. 31, which gives a cash runway into Q1 2027.

Price: 1.17, Change: +0.08, Percent Change: +7.34